A Treatment Patterns and Side Effects of Hormonal Therapy in Breast Cancer Patients at Dr. Moewardi Hospital, Surakarta
DOI:
https://doi.org/10.54445/pharmademica.v5i2.137
Abstract View:
11
PDF downloads:
6
Keywords:
adverse drug reactions, breast cancer, hormonal therapy , tamoxifen, treatment patternAbstract
Breast cancer is one of the most prevalent malignancies in women and remains a leading cause of cancer-related mortality. One of the main treatment modalities for hormone receptor–positive breast cancer is Adjuvant Endocrine Therapy (AET), particularly tamoxifen, either as monotherapy or in combination. This study aimed to evaluate patient characteristics, treatment patterns of hormonal and chemotherapy regimens, as well as adverse drug reactions (ADRs) among breast cancer patients at Dr. Moewardi General Hospital, Surakarta. This study employed a cross-sectional design with purposive sampling. A total of 64 breast cancer patients who had received tamoxifen therapy for at least one month were included. Data were collected from medical records and questionnaires, and analyzed using the Chi-Square test to determine associations between variables. The results showed that most patients were <50 years old (60.9%) and diagnosed at advanced stages (III–IV, 57.8%). The most frequent treatment was a combination of chemotherapy and hormonal therapy (51.6%), while hormonal therapy alone was administered in 48.4% of patients. The most commonly prescribed chemotherapy regimen was Cyclophosphamide & Epirubicin, whereas the most frequent hormonal regimen was Tamoxifen + Zoladex. Bivariate analysis indicated significant associations between age and treatment type, as well as between cancer stage and treatment type (p<0,05). However, no significant associations were found between age, stage, or type of therapy and ADRs (p>0.05). The most commonly reported adverse effects were fatigue, hot flushes, nausea, and bone/joint pain, with a small proportion reporting endometrial cancer.
Downloads
References
Aprilianty, D., Rafidah, Suhrawardi, & Rusmilawaty. (2024). Studi Literatur Faktor Risiko Yang Berhubungan Dengan Kejadian Kanker Payudara Pada Wanita. Jurnal Cakrawala Ilmiah, 3(9), 2473–2486.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
Burstein, H. J., Demichele, A., Fallowfield, L., Somerfield, M. R., & Lynn Henry, N. (2024). Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer - Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. Journal of Clinical Oncology, 42(12), 1450–1453. https://doi.org/10.1200/JCO.24.00248
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 30(8), 1194–1220. https://doi.org/10.1093/annonc/mdz173
Dyanti, G. A. R., & Suariyani, N. L. P. (2016). Faktor-Faktor Keterlambatan Penderita Kanker Payudara Dalam Melakukan Pemeriksaan Awal Ke Pelayanan Kesehatan. Jurnal Kesehatan Masyarakat, 11(2), 276. https://doi.org/10.15294/kemas.v11i2.3742
Fadhil, M., Harahap, W. A., & Rusnita, D. (2019). Hasil Pengobatan Adjuvan Tamoxifen pada Pasien Kanker Payudara di RSUP Dr. M. Djamil Padang. Cdk-281, 46(12), 748–752.
Fallowfield, L. J., Hall, A., Maguire, G. P., & Baum, M. (1990). Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. British Medical Journal, 301(6752), 575–580. https://doi.org/10.1136/bmj.301.6752.575
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., Chen, N., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Jankowitz, R. C., Javid, S. H., Krishnamurthy, J., … Kumar, R. (2024). Breast Cancer, Version 3.2024. JNCCN Journal of the National Comprehensive Cancer Network, 22(5), 331–357. https://doi.org/10.6004/jnccn.2024.0035
Kemenkes RI. (2022). Profil Kesehatan Indonesia 2021. In Pusdatin.Kemenkes.Go.Id.
Manfrini, O., Cenko, E., Bergami, M., Yoon, J., Kostadinovic, J., Zdravkovic, D., Zdravkovic, M., & Bugiardini, R. (2025). Anticancer-Drug-Related Cardiotoxicity from Adjuvant Goserelin and Tamoxifen Therapy. Journal of Clinical Medicine, 14(2). https://doi.org/10.3390/jcm14020484
N’Da, D. D., Breytenbach, J. C., Smith, P. J., & Lategan, C. (2010). Synthesis, cytotoxicity and antimalarial activity of ferrocenyl amides of 4-aminoquinolines. Arzneimittel-Forschung/Drug Research, 60(10), 627–635. https://doi.org/10.1055/s-0031-1296337
Orrantia-Borunda, E., Achondo-Nunez, P., Acuna-Aguilar, Evelia, L., Gomez-Valles, Octavia, F., & Ramirez-Valdespino, Adriana, C. (2022). Chapter 3: Subtypes of Breast Cancer. In Subtype of Breast Cancer. https://pubmed.ncbi.nlm.nih.gov/36122153/
Regan, M. M., Pagani, O., Walley, B., Torrisi, R., Perez, E. A., Francis, P., Fleming, G. F., Price, K. N., Thürlimann, B., Maibach, R., Castiglione-gertsch, M., Coates, A. S., Goldhirsch, A., & Gelber, R. D. (2008). Premenopausal endocrine-responsive early breast cancer: Who receives chemotherapy? Annals of Oncology, 19(7), 1231–1241. https://doi.org/10.1093/annonc/mdn037
Shidqi, Z. N., Saraswati, L. D., Kusariana, N., Sutiningsih, D., & Udiyono, A. (2022). Faktor-Faktor Keterlambatan Diagnosis Kanker Pada Pasien Kanker Payudara : Systematic Review. Jurnal Epidemiologi Kesehatan Komunitas, 7(2), 471–481. https://doi.org/10.14710/jekk.v7i2.14911
Siska, M., Kusumastuti, T., & Cholisoh, Z. (2024). Gambaran Adverse Drud Reaction (ADRs) pada Pasien Kanker Payudara yang Mendapatkan Adjuvant Endocrine Therapy (AET) Tamoxifen dan Faktor-faktor yang Mempengaruhinya di RS Swasta Semarang Tahun 2023. Jurnal Ners Universitas Pahlawan, 8(1), 96–101. http://journal.universitaspahlawan.ac.id/index.php/ners
Sperry, L. (2020). Breast Cancer. Behavioral Health, 171–181. https://doi.org/10.4324/9780203084632-26
Sutrisno, Nurmalik, M. C. A., & Aripuspita, E. (2024). Hubungan Antara Usia Dan Lama Penggunaan Kontrasepsi Hormonal Dengan Stadium Pada Kanker Payudara Di Rsud Dr. Soegiri Lamongan. JurnalMU: Jurnal Medis Umum, 1(3), 198–208. https://doi.org/10.30651/jmu.v1i3.24776
American Cancer Society. (2019). Breast Cancer Facts & Figures 2019–2020. Atlanta: American Cancer Society.
ASCO Guidelines. (2022). Endocrine Therapy for Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology.
NCCN. (2024). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network.
The Global Cancer Observatory. (2021). Cancer Today. International Agency for Research on Cancer (IARC).
World Health Organization. (2022). Breast cancer: Prevention and control. WHO.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Niken Luthfiyanti, Vivin Marwiyati Rohmana, Muhammad Fuad Zidane Khusain
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
.png)
